F1ANNEX COMMON TECHNICAL SPECIFICATIONS (CTS) FOR IN VITRO DIAGNOSTIC MEDICAL DEVICES
3. COMMON TECHNICAL SPECIFICATIONS (CTS) FOR PRODUCTS REFERRED TO IN ANNEX II, LIST A OF DIRECTIVE 98/79/EC
3.1. CTS for performance evaluation of reagents and reagent products for the detection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 and 2), HTLV I and II, and hepatitis B, C, D
General principles
F23.1.1.
Devices which detect virus infections shall meet the requirements for sensitivity and specificity set out in Table 1 and Table 5 according to virus type and entities detected (antigen and/or antibody). See also principle 3.1.11 for screening assays.
3.1.2.
Devices intended by the manufacturer for testing body fluids other than serum or plasma, e.g. urine, saliva, etc., shall meet the same CTS requirements for sensitivity and specificity as serum or plasma tests. The performance evaluation shall test samples from the same individuals in both the tests to be approved and in a respective serum or plasma assay.
3.1.3.
Devices intended by the manufacturer for self-test, i.e. home use, shall meet the same CTS requirements for sensitivity and specificity as respective devices for professional use. Relevant parts of the performance evaluation shall be carried out (or repeated) by appropriate lay users to validate the operation of the device and the instructions for use.
3.1.4.
All performance evaluations shall be carried out in direct comparison with an established state-of-the-art device. The device used for comparison shall be one bearing F5UK or CE marking, if on the market at the time of the performance evaluation.
3.1.5.
If discrepant test results are identified as part of an evaluation, these results shall be resolved as far as possible, for example:
by evaluation of the discrepant sample in further test systems,
by use of an alternative method or marker,
by a review of the clinical status and diagnosis of the patient, and
by the testing of follow-up-samples.
3.1.6.
Performance evaluations shall be performed on a population equivalent to the European population.
3.1.7.
Positive specimens used in the performance evaluation shall be selected to reflect different stages of the respective disease(s), different antibody patterns, different genotypes, different subtypes, mutants, etc.
3.1.8.
Sensitivity with true positives and sero-conversion samples shall be evaluated as follows:
- 3.1.8.1.
Diagnostic test sensitivity during sero-conversion has to represent the state of the art. Whether further testing of the same or additional sero-conversion panels is conducted by the F7approved body or by the manufacturer the results shall confirm the initial performance evaluation data (see Table 1). Sero-conversion panels should start with a negative bleed(s) and should have narrow bleeding intervals.
- 3.1.8.2.
For blood screening devices (with the exception of HBsAg and anti-HBc tests), all true positive samples shall be identified as positive by the device to be F6UK or CE marked, (Table 1). For HBsAg and anti-HBc tests the new device shall have an overall performance at least equivalent to that of the established device (see 3.1.4).
- 3.1.8.3.
Regarding HIV tests:
all sero-conversion HIV samples shall be identified as positive, and
at least 40 early sero-conversion HIV samples shall be tested. Results should conform to the state of the art.
3.1.9.
Performance evaluation of screening assays shall include 25 positive (if available in the case of rare infections) ‘same day’ fresh serum and/or plasma samples (≤ 1 day after sampling).
3.1.10.
Negative specimens used in a performance evaluation shall be defined so as to reflect the target population for which the test is intended, for example blood donors, hospitalised patients, pregnant women, etc.
3.1.11.
For performance evaluations for screening assays (Table 1) blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first time donors.
3.1.12.
Devices shall have a specificity of at least 99,5 % on blood donations, unless otherwise indicated in the accompanying tables. Specificity shall be calculated using the frequency of repeatedly reactive (i.e. false positive) results in blood donors negative for the target marker.
3.1.13.
Devices shall be evaluated to establish the effect of potential interfering substances, as part of the performance evaluation. The potential interfering substances to be evaluated will depend to some extent on the composition of the reagent and configuration of the assay. Potential interfering substances shall be identified as part of the risk analysis required by the essential requirements for each new device but may include, for example:
specimens representing ‘related’ infections,
specimens from multipara, i.e. women who have had more than one pregnancy, or rheumatoid factor positive patients,
for recombinant antigens, human antibodies to components of the expression system, for example anti-E. coli, or anti-yeast.
3.1.14.
For devices intended by the manufacturer to be used with serum and plasma the performance evaluation must demonstrate serum to plasma equivalency. This shall be demonstrated for at least 50 donations (25 positive and 25 negative).
3.1.15.
For devices intended for use with plasma the performance evaluation shall verify the performance of the device using all anticoagulants which the manufacturer indicates for use with the device. This shall be demonstrated for at least 50 donations (25 positive and 25 negative).
3.1.16.
As part of the required risk analysis the whole system failure rate leading to false-negative results shall be determined in repeat assays on low-positive specimens.
3.1.17.
If a new in vitro diagnostic medical device belonging to Annex II List A is not specifically covered by the common technical specification, the common technical specification for a related device should be taken into account. Related devices may be identified on different grounds, e.g. by the same or similar intended use or by similar risks.
F23.2. Additional requirements for HIV and HCV antigen and antibody combined tests
3.2.1.
HIV antigen and antibody combined tests intended for the detection of HIV-1 p24 antigen and HIV-1/2 antibody shall meet the requirements for sensitivity and specificity set out in Table 1 and Table 5.
3.2.2.
Hepatitis C virus (HCV) antigen and antibody combined tests intended for the detection of HCV antigen and HCV antibody shall meet the requirements for sensitivity and specificity set out in Table 1 and Table 5. HCV seroconversion panels for the evaluation of HCV antigen and antibody combined tests shall start with one or more negative bleeds and comprise panel members from early HCV infection (HCV core antigen and/or HCV RNA positive but anti-HCV negative). HCV antigen and antibody combined tests shall demonstrate enhanced sensitivity in early HCV infection when compared to HCV antibody only tests.
3.3. Additional requirements for nucleic acid amplification techniques (NAT)
The performance evaluation criteria for NAT assays can be found in Table 2.
3.3.1.
For target sequence amplification assays, a functionality control for each test sample (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.
F23.3.2.
The analytical sensitivity or detection limit for NAT assays shall be expressed by the 95 % positive cut-off value. This is the analyte concentration where 95 % of test runs give positive results following serial dilutions of an international reference material, where available, such as a World Health Organisation (WHO) International Standard or reference material calibrated against a WHO International Standard.
F33.3.2a.
Qualitative HIV NAT assays intended to be used to detect the presence of HIV in blood, blood components, cells, tissues or organs, or in any of their derivatives, in order to assess their suitability for transfusion, transplantation or cell administration shall be designed to detect both HIV-1 and HIV-2.
3.3.2b.
Qualitative HIV NAT assays, other than virus typing assays, shall be designed to compensate for the potential failure of a HIV-1 NAT target region, e.g. by using two independent target regions.
3.3.3.
Genotype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped samples.
3.3.4.
Results of quantitative NAT assays shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.
3.3.5.
NAT assays may be used to detect virus in antibody negative samples, i.e. pre-sero-conversion samples. Viruses within immune-complexes may behave differently in comparison to free viruses, for example during a centrifugation step. It is therefore important that during robustness studies, antibody-negative (pre-sero-conversion) samples are included.
3.3.6.
For investigation of potential carry-over, at least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The high positive samples shall comprise samples with naturally occurring high virus titres.
3.3.7.
The whole system failure rate leading to false-negative results shall be determined by testing low-positive specimens. Low-positive specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration.
3.4. CTS for the manufacturer’s release testing of reagents and reagent products for the detection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 and 2), HTLV I and II, and hepatitis B, C, D (immunological assays only)
3.4.1.
The manufacturer’s release testing criteria shall ensure that every batch consistently identifies the relevant antigens, epitopes, and antibodies.
3.4.2.
The manufacturer’s batch release testing for screening assays shall include at least 100 specimens negative for the relevant analyte.
3.5. CTS for performance evaluation of reagents and reagent products for determining the following blood group antigens: ABO blood group system ABO1 (A), ABO2 (B), ABO3 (A,B); Rh blood group system RH1 (D), RH2 (C), RH3 (E), RH4 (c), RH5 (e); Kell blood group system KEL1 (K)
Criteria for performance evaluation of reagents and reagent products for determining the blood groups antigens: ABO blood group system ABO1 (A), ABO2 (B), ABO3 (A,B); Rh blood group system RH1 (D), RH2 (C), RH3 (E), RH4 (c), RH5 (e); Kell blood group system KEL1 (K) can be found in Table 9.
3.5.1.
All performance evaluations shall be carried out in direct comparison with an established state-of-the-art device. The device used for comparison shall be one bearing CE marking, if on the market at the time of the performance evaluation.
3.5.2.
If discrepant test results are identified as part of an evaluation, these results shall be resolved as far as possible, for example:
by evaluation of the discrepant sample in further test systems,
by use of an alternative method,
3.5.3.
Performance evaluations shall be performed on a population equivalent to the European population.
3.5.4.
Positive specimens used in the performance evaluation shall be selected to reflect variant and weak antigen expression.
3.5.5.
Devices shall be evaluated to establish the effect of potential interfering substances, as part of the performance evaluation. The potential interfering substances to be evaluated will depend to some extent on the composition of the reagent and configuration of the assay. Potential interfering substances shall be identified as part of the risk analysis required by the essential requirements for each new device.
3.5.6.
For devices intended for use with plasma the performance evaluation shall verify the performance of the device using all anticoagulants which the manufacturer indicates for use with the device. This shall be demonstrated for at least 50 donations.
3.6. CTS for the manufacturer’s release testing of reagents and reagent products for determining the blood group antigens: ABO blood group system ABO1 (A), ABO2 (B), ABO3 (A,B); Rh blood group system RH1 (D), RH2 (C), RH3 (E), RH4 (c), RH5 (e); Kell blood group system KEL1 (K)
3.6.1.
The manufacturer’s release testing criteria shall ensure that every batch consistently identifies the relevant antigens, epitopes, and antibodies.
3.6.2.
Requirements for manufacturers batch release testing are outlined in Table 10.
F43.7. CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening
CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening are set out in Table 11.
anti-HIV 1/2, HIV 1/2 Ag/Ab | Anti-HTLV-I/II | anti-HCV, HCV Ag/Ab | HBsAg | Anti-HBc | ||
|---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 400 HIV-1 100 HIV-2 including 40 non-B-subtypes, all available HIV/1 subtypes shall be represented by at least 3 samples per subtype | 300 HTLV-I 100 HTLV-II | 400 (positive samples) Including samples from different stages of infection and reflecting different antibody patterns. Genotype 1-4: > 20 samples per genotype (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | 400 including subtype-consideration | 400 including evaluation of other HBV-markers |
Sero-conversion panels | 20 panels 10 further panels (at F8Approved Body or manufacturer) | To be defined when available | 20 panels 10 further panels (at F8Approved Body or manufacturer) | 20 panels 10 further panels (at F8Approved Body or manufacturer) | To be defined when available | |
Analytical sensitivity | Standards | 0,130 IU/ml (WHO International Standard: Third International Standard for HBsAg, subtypes ayw1/adw2, HBV genotype B4, NIBSC code: 12/226) | ||||
Specificity | Unselected donors (including first-time donors) | 5 000 | 5 000 | 5 000 | 5 000 | 5 000 |
Hospitalized patients | 200 | 200 | 200 | 200 | 200 | |
Potentially cross-reacting blood-specimens (RF+, related viruses, pregnant women, etc.) | 100 | 100 | 100 | 100 | 100 |
HIV1 | HCV | HBV | HTLV I/II | Acceptance criteria | |||||
|---|---|---|---|---|---|---|---|---|---|
NAT | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative | qualitative | quantitative | |
As for HIV quantitative | As for HIV quantitative | As for HIV quantitative | |||||||
Sensitivity Detection limit Detection of analytical sensitivity (IU/ml; defined on WHO standards or calibrated reference materials) | According to EP validation guideline 3 : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | Detection limit: as for qualitative tests; Quantification limit: dilutions (half-log10 or less) of calibrated reference preparations, definition of lower, upper quantification limit, precision, accuracy, ‘ linear ’ measuring range, ‘ dynamic range ’ . Reproducibility at different concentration levels to be shown | According to EP validation guideline 3 : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | According to EP validation guideline 3 : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | According to EP validation guideline 3 : several dilution series into borderline concentration; statistical analysis (e.g. Probit analysis) on the basis of at least 24 replicates; calculation of 95 % cut-off value | ||||
Genotype/subtype detection/quantification efficiency | At least 10 samples per subtype (as far as available) | Dilution series of all relevant genotypes/subtypes, preferably of reference materials, as far as available | At least 10 samples per genotype (as far as available) | As far as calibrated genotype reference materials are available | As far as calibrated genotype reference materials are available | ||||
Cell culture supernatants (could substitute for rare HIV-1 subtypes) | Transcripts or plasmids quantified by appropriate methods may be used. | ||||||||
According to EP validation guideline 3 as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline 3 as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline 3 as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | According to EP validation guideline 3 as far as calibrated subtype reference materials are available; in vitro transcripts could be an option | ||||||
Diagnostic specificity negative samples | 500 blood donors | 100 blood donors | 500 blood donors | 500 blood donors | 500 individual blood donations | ||||
Potential cross-reactive markers | By suitable assay design evidence (e.g. sequence comparison) and/or testing of at least 10 human retrovirus (e.g. HTLV)-positive samples | As for qualitative tests | By assays design and/or testing of at least 10 human flavivirus (e.g. HGV, YFV) positive samples | By assays design and/or testing of at least 10 other DNA-virus positive samples | By assay design and/or testing of at least 10 human retrovirus (e.g. HIV-) positive samples | ||||
Robustness | As for qualitative tests | ||||||||
Cross-contamination | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | At least 5 runs using alternating high positive (known to occur naturally) and negative samples | |||||
Inhibition | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | Internal control preferably to go through the whole NAT procedure | |||||
Whole system failure rate leading to false-neg results | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | At least 100 samples virus-spiked with 3 × the 95 % pos cut-off concentration | 99/100 assays positive | ||||
European Pharmacopoeia guideline. | |||||||||
Notes: Acceptance criteria for ‘whole system failure rate leading to false-neg results’ is 99/100 assays positive. For quantitative NATs a study shall be performed on at least 100 positive specimens reflecting the routine conditions of users (e.g. no pre-selection of specimens). Comparative results with another NAT test system shall be generated in parallel. For qualitative NATs a study on diagnostic sensitivity shall be performed using at least 10 sero-conversion panels. Comparative results with another NAT test system shall be generated in parallel. | |||||||||
Anti-HIV 1/2 | Anti-HCV | HBsAg | Anti-HBc | Anti-HTLV I/II | Acceptance criteria | ||
|---|---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays |
Sero-conversion panels | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | Same criteria as for screening assays | |
Diagnostic specificity | Negative specimens | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | 1 000 blood donations | ≥ 99 % (anti-HBc: ≥ 96 %) |
200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens | 200 clinical specimens | |||
200 samples from pregnant women | 200 samples from pregnant women | 200 samples from pregnant women | 200 samples from pregnant women | ||||
100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples | 100 potentially interfering samples |
Anti-HIV confirmatory assay | Anti-HTLV confirmatory assay | HCV supplementary assay | HBsAg confirmatory assay | Acceptance criteria | ||
|---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 200 HIV-1 and 100 HIV-2 | 200 HTLV-I and 100 HTLV-II | 300 HCV (positive samples) | 300 HBsAg | Correct identification as positive (or indeterminate), not negative |
Including samples from different stages of infection and reflecting different antibody patterns | Including samples from different stages of infection and reflecting different antibody patterns. Genotypes 1 – 4: > 20 samples (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | Including samples from different stages of infection 20 ‘high pos’ samples (> 26 IU/ml); 20 samples in the cut-off range | ||||
Sero-conversion panels | 15 sero-conversion panels/low titre panels | 15 sero-conversion panels/low titre panels | 15 sero-conversion panels/low titre panels | |||
Analytical sensitivity | Standards | Second International Standard for HBsAg, subtype adw2, genotype A, NIBSC code: 00/588 | ||||
Diagnostic specificity | Negative specimens | 200 blood donations | 200 blood donation | 200 blood donations | 10 false positives as available from the performance evaluation of the screening assay 5 . | No false-positive results/ 5 no neutralisation |
200 clinical samples including pregnant women | 200 clinical samples including pregnant women | 200 clinical samples including pregnant women | ||||
50 potentially interfering samples, including samples with indeterminate results in other confirmatory assays | 50 potentially interfering samples including samples with indeterminate results in other confirmatory assays | 50 potentially interfering samples including samples with indeterminate results in other supplementary assays | 50 potentially interfering samples | |||
Acceptance criteria no neutralisation for HBsAg confirmatory assay. | ||||||
HIV-1 antigen and HIV Ag/Ab assays | HCV antigen and HCV Ag/Ab assays | Acceptance criteria | ||
|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 50 HIV-1 antigen positive 50 cell culture supernatants including different HIV-1 subtypes and HIV-2 | 25 HCV core antigen and/or HCV RNA positive but anti-HCV negative samples, comprising HCV genotypes 1-6 (if a genotype is not available, a justification shall be made) | See general principle in § 3.1.8 |
Sero-conversion panels 6 | 20 sero-conversion panels/low titre panels | 20 sero-conversion panels/low titre panels | ||
Analytical sensitivity | Standards | HIV-1 p24 Antigen, First International Reference Reagent, NIBSC code: 90/636 | HCV core antigen detection limit shall be investigated using dilutions of the WHO International HCV core antigen Standard: (HCV core Ag product code: PEI 129096/12) | For HIV-1 p24 antigen: ≤ 2 IU/ml |
Diagnostic specificity | 200 blood donations 200 clinical samples 50 potentially interfering samples | 200 blood donations, 200 clinical samples, 50 potentially interfering samples | ≥ 99,5 % after neutralisation or, if no neutralisation test available, after resolution of the sample status according to general principles in § 3.1.5 | |
The total number of seroconversion panels for combined Ag/Ab assays (from tables 1 and 5) need not be greater than 30. | ||||
HCV serotyping and genotyping assay | Acceptance criteria | ||
|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 200 (positive samples) Including samples from different stages of infection and reflecting different antibody patterns. Genotypes 1 – 4: > 20 samples (including non-a subtypes of genotype 4); 5: > 5 samples; 6: if available | ≥ 95 % agreement between serotyping and genotyping X1> 95 % agreement between genotyping and sequencing |
Diagnostic specificity | Negative specimens | 100 | |
Anti-HBs | Anti-HBc IgM | Anti-HBe | HBeAg | Acceptance criteria | ||
|---|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 100 vaccinees | 200 | 200 | 200 | ≥ 98 % |
100 naturally infected persons | Including samples from different stages of infection (acute/chronic, etc.) The acceptance criteria should only be applied on samples from acute infection stage. | Including samples from different stages of infection (acute/chronic, etc.) | Including samples from different stages of infection (acute/chronic, etc.) | |||
Sero-conversion panels | 10 follow-ups or anti-HBs sero-conversions | When available | ||||
Analytical sensitivity | Standards | WHO First International Reference Preparation 1977; NIBSC, United Kingdom | HBe — Referenzantigen 82; PEI Germany | Anti-HBs: < 10 mIU/ml | ||
Diagnostic specificity | Negative specimens | 500 | 200 blood donations | 200 blood donation | 200 blood donations | ≥ 98 % |
Including clinical samples | 200 clinical samples | 200 clinical samples | 200 clinical samples | |||
50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples | |||
Anti-HDV | Anti-HDV IgM | Delta antigen | Acceptance criteria | ||
|---|---|---|---|---|---|
Diagnostic sensitivity | Positive specimens | 100 | 50 | 10 | ≥ 98 % |
Specifying HBV markers | Specifying HBV markers | Specifying HBV markers | |||
Diagnostic specificity | Negative specimens | 200 | 200 | 200 | ≥ 98 % |
Including clinical samples | Including clinical samples | Including clinical samples | |||
50 potentially interfering samples | 50 potentially interfering samples | 50 potentially interfering samples | |||
1 | 2 | 3 | |
|---|---|---|---|
Specificity | Number of tests per recommended method | Total number of samples to be tested for a launch product | Total number of samples to be tested for a new formulation, or use of well-characterised reagents |
Anti-ABO1 (anti-A), anti-ABO2 (anti-B), anti-ABO3 (anti-A,B) | 500 | 3 000 | 1 000 |
Anti-RH1 (anti-D) | 500 | 3 000 | 1 000 |
Anti-RH2 (anti-C), anti-RH4 (anti-c), anti-RH3 (anti-E) | 100 | 1 000 | 200 |
Anti-RH5 (anti-e) | 100 | 500 | 200 |
Anti-KEL1 (anti-K) | 100 | 500 | 200 |
Acceptance criteria:
All of the above reagents shall show comparable test results with established reagents with acceptable performance with regard to claimed reactivity of the device. For established reagents, where the application or use has been changed or extended, further testing should be carried out in accordance with the requirements outlined in column 1 (above).
Performance evaluation of anti-D reagents shall include tests against a range of weak RH1 (D) and partial RH1 (D) samples, depending on the intended use of the product.
Qualifications:
- Clinical samples
10 % of the test population
- Neonatal specimens
> 2 % of the test population
- ABO samples
> 40 % A, B positives
- ‘weak D’
> 2 % of RH1 (D) positives
Table 10
Batch release criteria for reagents and reagent products to determine blood group antigens in the ABO, Rh and Kell blood group systems
Specificity testing requirements on each reagent
1. Test reagents
Blood group reagents | Minimum number of control cells to be tested | |||||||
|---|---|---|---|---|---|---|---|---|
Positive reactions | Negative reactions | |||||||
A1 | A2B | Ax | B | 0 | ||||
Anti-ABO1 (anti-A) | 2 | 2 | 2 9 | 2 | 2 | |||
B | A1B | A1 | 0 | |||||
Anti-ABO2 (anti-B) | 2 | 2 | 2 | 2 | ||||
A1 | A2 | Ax | B | 0 | ||||
Anti-ABO3 (anti-A,B) | 2 | 2 | 2 | 2 | 4 | |||
R1r | R2r | WeakD | r’r | r’r | rr | |||
Anti-RH1 (anti-D) | 2 | 2 | 2 9 | 1 | 1 | 1 | ||
R1R2 | R1r | r’r | R2R2 | r’r | rr | |||
Anti-RH2 (anti-C) | 2 | 1 | 1 | 1 | 1 | 1 | ||
R1R2 | R1r | r’r | R1R1 | |||||
Anti-RH4 (anti-c) | 1 | 2 | 1 | 3 | ||||
R1R2 | R2r | r’r | R1R1 | r’r | rr | |||
Anti-RH 3 (anti-E) | 2 | 1 | 1 | 1 | 1 | 1 | ||
R1R2 | R2r | r’r | R2R2 | |||||
Anti-RH5 (anti-e) | 2 | 1 | 1 | 3 | ||||
Kk | kk | |||||||
Anti-KEL1 (anti-K) | 4 | 3 | ||||||
Only by recommended techniques where reactivity against these antigens is claimed. | ||||||||
Note: Polyclonal reagents must be tested against a wider panel of cells to confirm specificity and exclude presence of unwanted contaminating antibodies. | ||||||||
Acceptance criteria:
Each batch of reagent must exhibit unequivocal positive or negative results by all recommended techniques in accordance with the results obtained from the performance evaluation data.
2. Control materials (red cells)
The phenotype of red cells used in the control of blood typing reagents listed above should be confirmed using established device.
Material | Number of specimens | Acceptance Criteria | |
|---|---|---|---|
Analytical sensitivity | vCJD brain spikes in human plasma (WHO reference number NHBY0/0003) | 24 replicates of each of three dilutions of the material WHO number NHBY0/0003 (1×10 4 , 1×10 5 , 1×10 6 ) | 23 of the 24 replicates detected at 1×10 4 |
vCJD spleen spikes in human plasma (10 % spleen homogenate — NIBSC reference number NHSY0/0009) | 24 replicates of each of three dilutions of the material NIBSC number NHSY0/0009 (1×10, 1×10 2 , 1×10 3 ) | 23 of the 24 replicates detected at 1×10 | |
Diagnostic sensitivity |
| As many specimen as reasonably possible and available, and at least 10 specimens | 90 % |
| As many specimen as reasonably possible and available, and at least 10 specimens | 90 % | |
Only in case where 10 specimens are not available:
| no more than one false negative result | ||
Analytical specificity | Potentially cross-reacting blood-specimens | 100 | |
Diagnostic specificity | Normal human plasma samples from area of low BSE exposure | 5 000 | At least 99,5 % |
Substituted by Commission Decision of 27 November 2009 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (notified under document C(2009) 9464) (Text with EEA relevance) (2009/886/EC).